The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study

Frontiers in Medicine

article

Ennio Giulio Favalli¹  Andrea Gobbini³  Mauro Bombaci³  Gabriella Maioli¹  Martina Biggioggero¹  Elisa Pesce³  Andrea Favalli³  Martina Martinovic³  Tanya Fabbris³  Edoardo Marchisio⁴  Alessandra Bandera⁵  Andrea Gori⁵  Sergio Abrignani³  Renata Grifantini³  Roberto Caporali¹ 

[1] Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute;Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano;Istituto Nazionale Genetica Molecolare;Dia.Pro;Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico;Department of Pathophysiology and Transplantation, Università degli Studi di Milano;Centre for Multidisciplinary Research in Health Science ,(MACH), Università degli Studi di Milano

关键词: seroprevalence;    SARS-CoV-2;    humoral response;    rheumatic musculoskeletal diseases;    disease-modifying anti-rheumatic drugs;    risk of infection;    COVID-19;   

DOI  :  10.3389/fmed.2022.850858

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Objectives Given the high occurrence of asymptomatic subsets, the true prevalence of SARS-CoV-2 infection in rheumatic patients is still underestimated. This study aims to evaluate the seroprevalence of SARS-CoV-2 antibodies in rheumatic musculoskeletal diseases (RMD) patients receiving immunomodulatory drugs. Methods All consecutive patients with rheumatoid arthritis or spondyloarthritis receiving disease-modifying antirheumatic drugs (DMARDs) evaluated between 4th May and 16th June 2020 were included. All participants were tested for anti-SARS-CoV-2 antibodies (IgG, IgM, IgA) by ELISA and were questioned about previous COVID-19 symptoms and clinical course. Results were compared with healthy population from the same region and with a control group of healthy subjects diagnosed with confirmed COVID-19. Results The study population includes 358 patients. The overall prevalence of anti-SARS-CoV-2 antibodies (18.4%) was higher than prevalence rate based on swab-positivity (1.12%) or clinically suspected cases (10.6%), but consistent with seroprevalence observed in the healthy population. Among seropositive patients 58% were asymptomatic. Mean anti-SARS-CoV-2 titer was comparable with the control group. No differences in seroprevalence were observed according to age, sex, rheumatic disease and treatment with conventional, biologic or targeted synthetic DMARDs, whereas glucocorticoids and comorbidities resulted in higher seroprevalence rate. Conclusions The results of this study are reassuring about the low impact of RMDs and immunomodulatory therapies on the risk and clinical course of COVID-19 and on humoral immune response to SARS-CoV-2 infection.

【 授权许可】

CC BY